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In MAG-camptothecin (MAG-CPT), the topoisomerase inhibitor camptothecin is linked to a water-soluble polymer. Preclinical
experiments showed enhanced antitumour efficacy and limited toxicity compared to camptothecin alone. Prior phase I trials guided
the regimen used in this study. The objectives were to determine the maximum tolerated dose, dose-limiting toxicities, safety profile,
and pharmacokinetics of weekly MAG-CPT. Patients with solid tumours received MAG-CPT intravenously administered weekly for 3
weeks in 4-week cycles. At the starting dose level (80mgm
 2week
 1), no dose-limiting toxicities occurred during the first cycle
(n¼3). Subsequently, three patients were enrolled at the second dose level (120mgm
 2 week
 1). Two of three patients at the
80mgm
 2week
 1 cohort developed haemorrhagic cystitis (grade 1/3 dysuria and grade 2/3 haematuria) during the second and third
cycles. Next, the 80mgm
 2week
 1 cohort was enlarged to a total of six patients. One other patient at this dose level experienced
grade 1 haematuria. At 120mgm
 2week
 1, grade 1 bladder toxicity occurred in two of three patients. Dose escalation was stopped
at 120mgm
 2week
 1. Cumulative bladder toxicity was dose-limiting toxicity at 80mgm
 2week
 1. Pharmacokinetics revealed
highly variable urinary camptothecin excretion, associated with bladder toxicity. Due to cumulative bladder toxicity, weekly MAG-
CPT is not a suitable regimen for treatment of patients with solid tumours.
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Camptothecins (CPTs) are a maturing class of anticancer agents
with significant clinical activity against a broad range of
malignancies (Kim and Lim, 2002). As the topoisomerase I
inhibitor CPT is extremely insoluble, the first phase I trials in
the early 1970s were performed with the less active water-soluble
carboxylate salt of CPT (Gottlieb et al, 1970; Muggia et al, 1972).
Although some antitumour activity was observed, severe haema-
tologic toxicity and haemorrhagic cystitis hampered the first
development. The observation that an acidic environment (e.g.
urine) favours the formation of the insoluble CPT lactone
suggested an explanation for the prolonged bladder toxicity
observed with sodium CPT, as well as a potential approach for
alleviating this toxic effect by alkalisation of the urine.
In MAG-camptothecin (MAG-CPT, PNU-166148), CPT is
covalently linked to a water-soluble polymer (MAG). MAG-CPT
is a copolymer of N-(hydroxypropyl)methacrylamide, (20-O-(N-
methacryloyl-glycyl-aminohexanoyl-glycyl)camptothecin) and N-
(2-hydroxypropyl) methacryloyl-glycinamide. Binding of polymers
to cytotoxic drugs may enhance the therapeutic activity and reduce
toxicity mainly by altering their pharmacokinetics and biodis-
tribution (Kim and Lim, 2002). Via the so-called enhanced
permeability and retention effect, polymeric drug conjugates
facilitate the solid tumour targeting of chemotherapeutic agents,
in both animal models and man (Maeda and Matsumura, 1989;
Duncan, 1999). This enhanced permeability and retention effect
can be attributed to leaky tumour vessels allowing macromolecular
extravasation not occurring in normal tissues and lack of effective
tumour lymphatic drainage preventing clearance of the penetrant
macromolecules and promoting their accumulation (Duncan,
1999). The enhanced permeability and retention effect has been
observed in many experimental and human solid tumours (Maeda
et al, 2000).
Experiments in healthy mice showed about five-fold lower
plasma levels of MAG-CPT compared to the highest tolerated dose
of CPT administered in classical vehicles (Caiolfa et al, 2000).
Whole-body autoradiographs in HT29 human colon carcinoma-
bearing mice demonstrated evident tumour radioactivity uptake
after intravenous injection of MAG-(
3H)CPT, but not after
injection of (
3H)CPT (Caiolfa et al, 2000). MAG-CPT was better
tolerated and tumour inhibition was observed at similar and even
lower doses compared to CPT alone (Caiolfa et al, 2000).
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lRecently, two phase I studies with MAG-CPT have been
performed. The first study indicated that a single dose of
200mgm
 2 MAG-CPT in a 4-week schedule caused no toxicity
(De Bono et al, 2000), while at 240mgm
 2 three dose-limiting
toxicities (DLTs) (neutropenic sepsis, grade 4 thrombocytopenia
and grade 3 diarrhoea) occurred. In the second study, patients with
solid tumours received MAG-CPT administrated over 3 consecu-
tive days every 4 weeks (Schoemaker et al, 2002). Dose-limiting
toxicity was cumulative bladder toxicity, occurring in two out of
three patients treated at a dose of 85mgm
 2day
 1. Pharmacoki-
netic analysis in both studies showed that carrier-bound CPT has
linear kinetics. The area under the curves (AUCs) following
administration of MAG-CPT as a single dose or administration
over three consecutive days are comparable. However, the
maximum plasma concentration (Cmax) levels of carrier-bound
and released CPT were three to five times lower when MAG-CPT
was administered over three consecutive days, compared to a
single dose administration. Therefore, when exposure to CPT is
similar for both administrations, a lower Cmax might give less
toxicity. However, as a result of the relatively long half-life of both
bound and free CPT, accumulation in plasma was observed during
the 3 days of administration. This accumulation might be the
explanation for the dose-related toxicity observed in this trial,
suggesting that toxicity can be avoided by increasing the time
between dosing (Schoemaker et al, 2002). This answer was sought
in the present study.
In this phase I trial, MAG-CPT was administered weekly for 3
weeks in a 4-week cycle in adult patients with refractory or
resistant solid tumours. The primary objectives were to determine
the maximum tolerated dose and DLTs, and to define the safety
profile of MAG-CPT. The secondary objective was the evaluation
of pharmacokinetics. Based on the results of the above-mentioned
phase I studies, a starting dose of 80mgm
 2week
 1 was chosen
(total dose 240mgm
 2cycle
 1).
PATIENTS AND METHODS
Patient selection
The study was performed in Leuven, Belgium and Groningen, The
Netherlands. Patients were included if they had histological or
cytological confirmed malignant tumours for whom no recognised
therapy was available. Patients may have received prior chemo-,
hormone-, or immunotherapy. Patients must have completed any
prior chemotherapy 4 weeks before study entry. Previous
treatment with CPTs (e.g. topotecan, irinotecan, 9-AC) was not
allowed. Prior radiotherapy was allowed as long as no more than
25% of the bone marrow was irradiated. Patients had to be
recovered from all acute toxic effects from any prior therapy,
excluding alopecia and Common Toxicity Criteria (CTC) grade 1
neurotoxicity residual from prior chemotherapy. Patients (X18
years) had to have a performance status p2 according to the
Eastern Cooperative Oncology Group (ECOG) scale, and a life
expectancy of at least 12 weeks. Adequate organ functions were
required such as bone marrow function (neutrophils
X1.5 10
9l
 1 and platelets X100 10
9l
 1), renal function
(serum creatinine o133mmoll
 1) and liver function, defined as
total bilirubin, serum alanine aminotransferase (ALAT) and serum
aspartate aminotransferase (ASAT) within the normal range, or for
patients with liver metastases serum ALAT and ASAT less than five
times the upper limit of normal and total bilirubin less than 1.5
times the upper limit of normal. Patients with haematologic
malignancies, known brain or leptomeningeal disease, more than
three prior chemotherapy regimens, previous high-dose che-
motherapy requiring (autologous) bone marrow transplantation
or peripheral stem cell reconstitution, and known hepatitis B or
HIV positive or AIDS-related illness were excluded. Pregnant or
breast feeding women, or fertile persons not using contraceptives,
were also excluded. The study was approved by the medical ethics
committees of both hospitals. All patients gave written informed
consent.
Treatment schedule, dose escalation and dose adjustments
MAG-CPT (provided by Pfizer, Nerviano (Milan), Italy) was
administered intravenously in 4-week cycles comprising weekly
treatment for three consecutive weeks, followed by 1-week rest.
Toxicities were graded according to the CTC of the National
Cancer Institute. Dose-limiting toxicities were defined as any of the
following events occurring during the first cycle of treatment with
MAG-CPT: grade 4 granulocytopenia lasting at least 7 days, febrile
neutropenia, neutropenic infection, grade 3 or 4 thrombocytope-
nia, grade 3 or 4 nonhaematologic toxicity and grade 2
neurotoxicity. Failure to complete the first treatment cycle with
three full-weekly doses within a maximum of 6 weeks due to drug-
related toxicity was also considered as DLT.
At least three patients were to be treated at the starting dose of
80mgm
 2week
 1. One patient was treated and observed for 3
weeks from the start of treatment. Thereafter, the second and third
patients started with MAG-CPT in the absence of DLTs in the first
patient. The latter were observed for at least 3 weeks. If DLT
occurred already at the 80mgm
 2week
 1 (240mgm
 2cycle
 1)
dose level, subsequent treatment would be given at a dose level of
60mgm
 2week
 1 (180mgm
 2cycle
 1). If no DLTs or clinically
significant toxicity occurred during the first cycle at the starting
dose level, further dose escalation would proceed in cohorts of
three patients by modified Fibonacci-guided dose increments
defined by the investigators on the basis of the clinical and
pharmacokinetic results. At subsequent dose levels, three patients
were to be enrolled in parallel. At any dose level, if one out of three
patients would experience in the first cycle a DLT, the patient
cohort had to be enlarged to a total of six patients. If no other DLT
or clinically significant toxicity was observed at this dose level,
dose escalation would proceed at the next dose increments. The
maximum tolerated dose was reached when X2 out of three or X2
out of six patients experience a DLT. Upon identification of the
maximum tolerated dose, at least six patients would be treated at
the next lower dose level, to better characterise the safety profile at
that dose. The next dose level below the maximum tolerated dose
would be the starting dose recommended for use in subsequent
phase II studies. No within-patient dose escalation was foreseen.
Dose modifications during a cycle were based on worst toxicity
attributable to the study drug observed during that given cycle. In
case of grade 3/4 granulocytopenia, grade 3/4 thrombocytopenia,
febrile neutropenia, neutropenic infection, grade 2–4 neurological
toxicity and grade 3/4 other nonhaematologic toxicities, treatment
was stopped for the given cycle. Dose adjustment at the start of
subsequent cycles was based on the assessment of toxicity during
the previous cycle. When patients experienced grade 2–4
granulocytopenia, grade 2–4 thrombocytopenia, grade 1–4
neurotoxicity, or other grade 2–4 nonhaematologic toxicities,
treatment was delayed until recovery. If re-treatment had to be
held for more than 2 weeks, the patient was removed from therapy.
Prophylactic treatment with antiemetics was not provided at the
first dose during the first cycle of treatment. Afterwards,
antiemetic prophylactics could be administered based on the
judgement of the physician. For diarrhoea loperamide was allowed.
Treatment evaluation
Patient evaluation on days 1, 8, 15 and 22 of each cycle included
complete blood cell counts, liver and renal functions, urinalysis,
performance status and toxicity scoring according to the CTC.
Tumour measurements were repeated at least every two cycles.
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(Therasse et al, 2000).
Pharmacokinetics
During the first cycle of treatment, blood samples were collected
for pharmacokinetic analysis of MAG-CPT and free CPT. On days
1 and 15, blood samples were drawn just before infusion,
immediately after infusion, at 10min after the end of infusion,
and at 1, 4, 8, 12 and 24h post-infusion. On day 8, one sample was
taken prior to infusion, and one at the end of infusion. On days 22
and 29, one blood sample was collected. Pre-cooled heparinised
tubes were used for sampling and were immediately placed on ice
until being centrifuged at 1200g at 41C for 10min. For
determination of free CPT levels, 0.25ml plasma was added to
tubes containing 0.75ml 8.5% phosphoric acid and subsequently
mixed. Specimens were stored at  801C until analysis.
Urine portions were collected during the first cycle on day 1,
before the first dose, and post-dose with timed collections between
0–8 and 8–24h after infusion. Subsequently, urine samples were
taken weekly until the start of the second cycle. An aliquot of each
urine portion was stored at  201C until analysis.
A high-performance liquid chromatographic (HPLC) method
with fluorescence detection was used for determination of CPT in
plasma and urine (Fraier et al, 2000). Total CPT levels were
determined after hydrolysis of MAG-CPT. Free CPT was extracted
from acidified plasma before determination. Bound CPT was
calculated by the difference of total minus free CPT. In urine, only
total CPT levels were measured. The lower limit of quantification
in plasma was 10ngml
 1 for total CPT and 1ngml
 1 for free CPT.
In urine, the lower limit of quantification for total CPT was
50ngml
 1.
Pharmacokinetic calculations for carrier-bound and free CPT
were performed using both a noncompartmental and compart-
mental approach. Noncompartmental analysis was executed with
the WinNonLin package (version 2.1, Scientific Consulting Inc.).
Compartmental analysis was carried out with the MW\Pharm
(version 3.5, Mediware, Groningen, The Netherlands) and ADAPT
II (version 4.0, USC, Los Angeles, USA) packages. Curve stripping
and subsequent curve fitting was performed in the KINSTRIP and
KINFIT programs of the MW\Pharm package. These data were
subsequently used in a multi-compartment analysis in ADAPT II,
in which the combined data of carrier bound and free CPT in
plasma and the amount CPT excreted in urine were analysed.
Variance for the observations was assumed to be proportional to
the measured values and set at 10%.
The percentage of the administered dose recovered in urine over
the first 24h was calculated as the amount excreted in urine
divided by the total administered dose. The creatinine clearance
before treatment was determined according to the Cockroft and
Gault formula (Cockcroft and Gault, 1976).
RESULTS
Patient characteristics and treatment
Between August 2000 and January 2001, nine patients (four males
and five females) were included in the study. Patient character-
istics are listed in Table 1. Patients received a total of 20 cycles,
with a median of two (range 1–4) cycles per patient.
Toxicity
Initially, three patients were enrolled at a dose level of
80mgm
 2week
 1. No DLTs occurred during the first cycle of
treatment. Subsequently, three patients were enrolled in parallel at
the next dose level of 120mgm
 2week
 1. As the trial continued,
two of the three enrolled patients at the first dose level developed
chemical cystitis, inducing cumulative bladder toxicity (Table 2).
One patient at the first dose level developed bladder toxicity
during the second cycle (grade 1 dysuria and grade 2 haematuria).
Table 1 Patient characteristics
Patients entered 9
Male/female 4/5
Median age, years (range) 55 (26–74)
Performance status
03
16
Malignancy
Melanoma 1
Non-small-cell lung cancer 4
Sarcoma 3
Renal cell carcinoma 1
Prior therapy
Chemotherapy 8
Radiotherapy 2
Immunotherapy 1
Hormonal therapy 1
Table 2 Bladder toxicity per individual patient per cycle according to CTC
CTC grade dysuria CTC grade haematuria
Cycle Cycle
1 2341 2 3 4
Cohort 1 (80mgm
 2)
Patient 1 0 0 0 0 0 0 0 0
Patient 2 0 1 — — 0 2 — —
Patient 3 0 2 3 1 1 2 3 1
Patient 7 0 0 — — 0 0 — —
Patient 8 0 0 — — 1 1 — —
Patient 9 0 — — — 0 — — —
Cohort 2 (120mgm
 2)
Patient 4 0 0 0 — 0 0 0 —
Patient 5 0 — — — 1 — — —
Patient 6 1 — — — 0 — — —
0¼no toxicity, 1–4¼toxicity grade according to CTC, —¼treatment discontinued.
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tinued. In another patient at the first dose level, bladder toxicity
worsened from grade 1 haematuria during the first cycle to grade 2
dysuria and haematuria during the second cycle, and to grade 3
dysuria and haematuria during the third cycle. During the fourth
cycle, the dose of MAG-CPT was reduced to 60mgm
 2week
 1.
Subsequently, treatment in this patient was stopped because of
progressive disease. Two out of three patients at the second dose
level experienced grade 1 bladder toxicity during their first cycle.
Treatment of both patients was discontinued after the first cycle
for progressive disease (Table 2). Owing to the observed
cumulative bladder toxicity, it was decided to enlarge the first
cohort (80mgm
 2week
 1) to a total of six patients. Although only
grade 1 bladder toxicity occurred in the three additional patients,
bladder toxicity in the second and third patients of the first dose
level was considered as DLT. Subsequently, it was decided to stop
the trial. De-escalation to a lower dose level was not performed,
because this would not result in a higher maximum tolerated dose
compared to the previous phase I trial in which a single dose of
240mgm
 2 (in a 4-week schedule) was the maximum tolerated
dose (De Bono et al, 2000).
Haematologic toxicity was mild (Table 3). Six patients
experienced grade 1 or 2 anaemia. Grade 1 thrombocytopenia,
grade 1 leucopenia, and grade 1 granulocytopenia were observed in
two, three, and two patients, respectively. No febrile neutropenia
was observed, and red blood cell or platelet transfusions were not
required.
With the exception of bladder toxicity, nonhaematologic toxicity
is listed in Table 4. Elevation of serum transaminases was seen in
one patient with non-small-cell lung cancer and progression of
liver metastases after one cycle. Other toxicities were grade 1
elevation of serum bilirubin and creatinine, grade 1 mucositis,
nausea, diarrhoea, skin reaction (rash), anorexia and fatigue. A few
patients experienced grade 2 nausea, vomiting, fever, infection, or
fatigue.
Overall, chemical cystitis induced grade 1–3 dysuria and/or
grade 1–3 haematuria in five out of the nine (56%) patients
included in this trial. Dose-limiting toxicity was cumulative
bladder toxicity, and 80mgm
 2week
 1 was considered to be the
maximum tolerated dose. The reason for treatment discontinua-
tion was progressive disease in eight patients, and bladder toxicity
in one patient.
Tumour response
No objective tumour responses were seen in six evaluable patients.
In two patients the best overall response was stable disease.
Pharmacokinetics
MAG-CPT plasma data followed a bi- or triexponential elimination
pattern in all patients. Simulation of CPT release in the first 24h
after infusion in a two- or three-compartment model with
elimination from the first compartment suggested that only 14–
20% of the administered dose (expressed as CPT equivalents) had
been eliminated after 24h. Since 26–92% of the dose was
recovered in urine after 24h, this model seems incorrect.
Modelling of CPT data in a one-compartment model, while
considering MAG-CPT as a mixture of two or three substances
each with a different elimination rate, revealed that 60–100% of
CPT might have been eliminated after 24h. One-compartment
Table 3 Worst haematologic CTC toxicity grade per patient
80mgm
 2
(no. of patients)
120mgm
 2
(no. of patients)
Anaemia
12 0
22 2
Thrombocytopenia
11 1
20 0
Leukopenia
12 1
20 0
Granulocytopenia
12 0
20 0
Table 4 Worst nonhaematologic CTC toxicity grade per patient
a
80mgm
 2
(No. of patients)
120mgm
 2
(No. of patients)
Bilirubin
110
200
ASAT
100
201
ALAT
100
200
3/4 0 1
Creatinine
131
200
Mucositis
130
200
Nausea
133
210
Vomiting
100
210
Diarrhoea
101
200
Fever
100
210
Infections
100
210
Skin reactions
110
200
Anorexia
120
200
Fatigue
110
221
aExcept bladder toxicity.
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The main pharmacokinetic parameters of carrier-bound CPT and
free CPT in plasma at the first week of treatment are shown in
Table 5. The fact that the Cmax and AUC0–168h of free CPT, in
patients treated with 80 vs 120mgm
 2, appeared similar might be
explained by the slow release rate of MAG-CPT. Possibly, the
period of sampling (between 0 and 24h after infusion) was too
short to determine the true Cmax of free CPT. Urinary excretion
during the first 24h after infusion expressed as a percentage of the
total dose administered, as well as the calculated creatinine
clearance before treatment, is shown in Table 6. We observed a
high variability in urinary excretion between subjects; after 24h,
between 26 and 92% of the total dose was excreted in patients
treated with 80 or 120mgm
 2 MAG-CPT. The calculated
creatinine clearance before treatment was not related to the
variability in urinary excretion. Figure 2 shows the relation
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Figure 1 Concentration vs time curve for MAG-CPT and free CPT in
plasma; values (mean7s.d.).
Table 5 Main pharmacokinetic parameters
a
Carrier-bound CPT
(plasma)
Free CPT
(plasma)
80mgm
 2(n¼6)
Cend, inf (mgml
 1) 36.6713.5
Cmax (ngml
 1) 102.2714.3
Tmax (h) 33.0710.6
AUC0-168h(mghl
 1) 15407449 10.371.2
V1 (l) 4.671.4
Vss(l) 15.6711.0
T1/2,a (h) 2.571.3
T1/2,b (h) 104.5724.1
b 42.9716.9
120mg/m
2 (n¼3)
Cend, inf (mgml
 1) 23.471.3
Cmax (ngml
 1) 85.5722.6
Tmax (h) 32.270.9
AUC0–168h(mghl
 1) 12267483 10.072.7
V1 (l) 4.771.9
Vss(l) 12.574.9
T1/2,a (h) 2.471.1
T1/2,b (h) 100.0719.8 84.8721.6
aValues (mean7s.d.) were obtained from the first week of treatment.
bn¼5, in one
patient carrier-bound CPT was not evaluable. Cend, inf¼concentration at the end of
infusion, Cmax¼maximum plasma concentration, Tmax¼time corresponding to the
maximum plasma concentration, AUC0–168: area under the plasma concentration–
time curve between 0 and 168h, V1¼initial volume of distribution, Vss¼volume of
distribution at steady state, T1/2,a¼initial half-life according to one-compartment
modelling, T1/2,b¼terminal half-life according to one-compartment modelling.
Table 6 Urinary excretion of CPT and creatinine clearance
Urinary excretion
a
(% of the dose)
Creatinine clearance
b
(before treatment, mlmin
 1)
Cohort 1 (80mgm
 2)
Patient 1 34.1 60.1
Patient 2 56.2 90.3
Patient 3 91.8 78.2
Patient 7 60.3 48.5
Patient 8 52.6 69.3
Patient 9 55.4 45.1
Mean7s.d. 58.4718.8 65.3717.5
Cohort 2 (120mgm
 2)
Patient 4 26.4 82.8
Patient 5 38.4 93.7
Patient 6 40.5 76.9
Mean7s.d. 35.177.6 84.578.5
aValues obtained from the first 24h of treatment (cycle 1).
bValues calculated by
Cockroft and Gault formula.
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observed in individual patients and the total amount of CPT
excreted during 24h after infusion (Spearman’s rho 0.82, Po0.01).
The relation between the worst bladder toxicity and the urine
production between 0 and 24h after infusion is also shown in
Figure 2 (Spearman’s rho  0.84, Po0.01). Figure 2 illustrates that
bladder toxicity is associated with local CPT exposure.
DISCUSSION
In this phase I study, MAG-CPT was administered weekly for 3
weeks in 4-week cycles in adult patients with solid tumours. Dose
escalation was already stopped when two patients at the starting
dose level developed a disabling haemorrhagic cystitis during the
second cycle. Other haematologic or nonhaematologic toxicity was
relatively mild. Dose-limiting toxicity was cumulative bladder
toxicity, and 80mgm
 2week
 1 was considered to be the
maximum tolerated dose. De-escalation to a lower dose level
(60mgm
 2week
 1) was not performed, because at this dose level a
higher maximum tolerated dose could not be reached compared to
the previous phase I trial in which a single dose of 240mgm
 2 (in
a 4-week schedule) was the maximum tolerated dose (De Bono
et al, 2000). Schoemaker et al (2002) showed that, also with MAG-
CPT infusion over 3 consecutive days, every 4 weeks the
cumulative bladder toxicity was dose-limiting. Dysuria and
haematuria, generally developing during the first or second cycle,
were noted in patients treated at 68mgm
 2day
 1 and higher dose
levels. As in the previous trials, no objective tumour responses
were observed in this trial. Without bladder protection, this weekly
regimen of MAG-CPT is not a suitable regimen for treatment of
patients with solid tumours.
The action of CPT is most evident in the S-phase of the cell
cycle; therefore, prolonged inhibition of topoisomerase I was
postulated to be an important parameter in causing cytotoxicity
(Hertzberg et al, 1989; Del Bino et al, 1991; Kingsbury et al, 1991;
Caiolfa et al, 2000). The relation between bladder toxicity and the
dose excreted in 24h suggests that bladder toxicity may be
explained by interindividual differences in pharmacokinetics.
Accumulation of both carrier-bound and free CPT during
subsequent cycles could not be assessed properly, because
pharmacokinetics were only performed during the first cycle of
treatment. However, clinical data did not demonstrate a reduction
in bladder toxicity in the weekly administration schedule
compared to the schedule with administration over 3 consecutive
days, suggesting that with weekly MAG-CPT treatment accumula-
tion in plasma still plays a role in inducing bladder toxicity.
Alkalisation of urine by treatment with sodium bicarbonate might
be a possible solution for MAG-CPT-induced bladder toxicity.
However, due to the relatively long terminal half-life of MAG-CPT
(about 100h) and the cumulative bladder toxicity after 4 weeks,
this treatment was not considered a suitable option. Whether the
uroprotective drug mesna has any effect on bladder toxicity
induced by MAG-CPT is currently unknown. As bladder toxicity is
associated with local CPT exposure, and an inverse relation
between urine volume and bladder toxicity was observed in this
trial, hyperhydration during MAG-CPT treatment might be useful
to reduce bladder toxicity.
Large and variable amounts of CPT are excreted in urine within
the first 24h after infusion. This might be largely due to the linkage
of CPT to the water-soluble MAG polymer, since CPT itself is
predominantly excreted into bile after intravenous administration
(Ahmed et al, 1996). The total urinary excretion of the water-
soluble CPT analogues irinotecan and topotecan is about 30 and
40%, respectively (Herben et al, 1996; Sparreboom et al, 1998). The
large amount of CPT excreted in urine after administration of
MAG-CPT cannot be explained in a multi-compartment pharma-
cokinetics analysis when only free CPT is supposed to be renally
excreted. The plasma levels of free CPT remain relatively low
during this period. The polyexponential elimination of MAG-CPT
suggests extensive distribution, but it is unlikely that the MAG-
CPT macromolecule distributes extensively throughout the body.
Therefore, we considered a classical two- or three-compartment
model with elimination from the first compartment physiologically
incorrect. The pharmacokinetic profile of MAG-CPT may be the
result of hybrid release characteristics of CPT from the macro-
molecule complex. If CPT becomes available with different release
rates from the macromolecule complex, rapidly released CPT can
account for the large amounts of free CPT found in urine within
24h after infusion, while more tightly bound CPT results in
sustained delivery of CPT from the complex. However, in vitro
hydrolysis in human plasma showed a free CPT recovery of less
than 10% after 24h of incubation at 371C. Moreover, in line with
the findings of Schoemaker et al (2002), we observed equal
elimination halve-lives for bound and free CPT, indicating that the
kinetics of free CPT are dependent on the release rate from its
carrier. Thus, not plasma, but certain tissue sites might be
responsible for the rapid release of free CPT into urine. Since renal
excretion is the main route of elimination, the kidney may be a
significant site of hydrolysis of CPT from its polymeric carrier.
Renal absorption and subsequent catabolism has previously been
shown to occur for drug–protein conjugates in proximal tubular
cells of the kidneys (Franssen et al, 1992). This might also be the
fate of drug–MAG polymers. Rapid elimination of CPT into urine
immediately after hydrolysis might explain why the free CPT
plasma levels remain relatively low.
In spite of the special pharmacokinetic properties of MAG-CPT,
a favourable impact on pharmacodynamics was not shown. An
interesting approach to investigate CPT accumulation in human
tumour tissue was recently published by Sarapa et al. Normal and
tumour tissue uptake of MAG-CPT was assessed in patients
undergoing elective surgery for colorectal carcinoma (Sarapa et al,
2003). Patients received a single dose of 60mgm
 2 of MAG-CPT
either 24h, 3 days, or 7 days prior to surgery. They demonstrated
delivery of CPT to the target tumour tissue and found the
equilibrium between plasma and tumour tissue concentrations of
released CPT being established within 24h after dosing. No
evidence for selective delivery or retention of MAG-CPT or
preferential release of free CPT in tumour tissue was found (Sarapa
et al, 2003).
Other phase I trials with polymeric drug conjugates based on N-
(2-hydroxypropyl)methacrylamide copolymers bound to doxor-
ubicin and paclitaxel have been performed (Muggia, 1999; Vasey
et al, 1999; Seymour et al, 2002). Vasey et al (1999) showed that
PK1 (doxorubicin covalently bound to N-(2-hydroxypropyl)-
methacrylamide) decreases doxorubicin DLTs, maintained anti-
tumour efficacy, and demonstrated no polymer-related toxicity. A
phase I study of PNU-166945 (a polymer-conjugated prodrug of
paclitaxel) was discontinued prematurely, mainly due to severe
neurotoxicity in additional rat studies (Meerum Terwogt et al,
2001).
Drug delivery based on polymers is an interesting approach in
the treatment of solid tumours. Binding of antitumour agents to
hydrophilic polymers can improve the solubility of poorly water-
soluble drugs and induce tumour targeting. However, polymeric
drug conjugates have an altered pharmacokinetic and toxicity
profile. Pharmacokinetics in this study revealed a direct associa-
tion between bladder toxicity and local CPT exposure. Due to
disabling bladder toxicity, weekly MAG-CPT is not a suitable
regimen.
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